Clinical bottom line
Chemotherapy-induced cognitive impairment (CICI), often termed "chemo brain," is a recognized but under-addressed complication in palliative care patients receiving chemotherapy, particularly those with advanced malignancies. Current evidence suggests that CICI manifests as deficits in memory, attention, executive function, and processing speed, adversely affecting quality of life. Management remains largely supportive and symptomatic, with emerging strategies emphasizing early recognition, multidisciplinary assessment, and non-pharmacological interventions. Pharmacologic treatments are limited and lack robust evidence. Clinicians should incorporate routine cognitive screening and tailor symptom management to individual patient needs, balancing cognitive symptom relief with overall palliative goals (Rasha et al., 2018; Li et al., 2021).
What the evidence shows
Chemotherapy-induced cognitive impairment affects a substantial subset of patients undergoing treatment for both solid tumors and hematological malignancies. Rasha et al. (2018) highlight that patients with hematological cancers frequently report cognitive deficits during and after chemotherapy, with symptoms persisting for months or longer. These impairments include difficulties with memory recall, concentration, and multitasking, which can compound psychological distress and reduce functional independence.
Li et al. (2021) examined colon and rectal carcinoma patients and found a significant association between chemotherapy-induced neuropathy and cognitive dysfunction, suggesting overlapping pathophysiological mechanisms such as neuroinflammation and oxidative stress. Cognitive impairment in this context correlates with diminished quality of life and increased psychological disorders, underscoring the need for integrated symptom management.
Janžič et al. (2026) provide a comprehensive overview of chemotherapy and targeted therapy effects on cognition, emphasizing that while some agents have higher neurotoxicity risk, individual susceptibility varies widely. They advocate for routine cognitive assessments in palliative care settings to detect early changes and guide interventions.
Non-pharmacological interventions, including cognitive rehabilitation, physical exercise, and psychosocial support, show promise in mitigating cognitive symptoms but require further validation in palliative populations. Pharmacologic options remain investigational, with no consensus on effective agents specifically for CICI (Clinical Journal of Oncology Nursing, 2023).
Caveats and uncertainty
The heterogeneity of chemotherapy regimens, cancer types, and patient comorbidities complicates the characterization and management of CICI. Most studies are observational or retrospective, limiting causal inference. There is a paucity of randomized controlled trials specifically addressing cognitive interventions in palliative care patients, and existing data often derive from younger or less frail populations.
Assessment tools for cognitive impairment vary, and standardized screening protocols in palliative care are lacking, potentially leading to underdiagnosis. The interplay between chemotherapy toxicity, psychological distress, fatigue, and other symptoms also confounds attribution of cognitive deficits solely to chemotherapy.
Pharmacologic treatments have not demonstrated consistent efficacy and may pose additional risks in frail patients with polypharmacy. Thus, management strategies must be individualized, weighing potential benefits against burdens.
How this may change practice
Palliative care clinicians should increase vigilance for cognitive changes in patients receiving chemotherapy, incorporating routine cognitive screening into clinical assessments. Early identification allows for timely supportive interventions, including patient and caregiver education, cognitive rehabilitation referrals, and psychosocial support.
Multidisciplinary collaboration with oncology, neuropsychology, and rehabilitation specialists can optimize care plans. Non-pharmacological approaches should be prioritized given the limited evidence for pharmacotherapy and the vulnerability of palliative populations.
Clinicians should also consider the impact of cognitive impairment on decision-making capacity and advance care planning discussions, adapting communication strategies accordingly. Research efforts are needed to develop validated screening tools and evidence-based interventions tailored to palliative care contexts.